Selected research from leading health care experts whose findings have a direct bearing on public policies effecting medical progress. Research is chosen based on its quality and relevance by the Medical Progress Today editorial staff.

Selected Research

Gene Therapy for Brain Tumors Shows Promise in Animals
Medscape, 7-18-05

Gene therapy, whereby a harmless virus is used as a vector to insert new genes into patients or to attack invading bacteria or cancer cells, has been a technology that has held much promise but scant performance, until now. This article reports findings in the July 20th issue of the International Journal of Cancer that:

Recombinant adeno-associated virus expressing tissue factor pathway inhibitor (rAAV-TFPI-2) inhibits invasion, angiogenesis and tumorigenesis of human glioblastomas in culture and in murine studies…

TFPI-2, a serine protease inhibitor, is underexpressed in malignant gliomas, Dr. Niranjan Yanamandra and colleagues from the University of Illinois College of Medicine, Peoria observe. Previous work has shown that overexpression of this protein in malignant glioma cells inhibits the invasive potential of tumor cells in vitro and in vivo.

Dr. Yanamandra's group now reports that successful rAAV-TFPI-2 infection of SNB19 malignant glioma cells significantly reduced migration and invasion of these cells in a dose-dependent manner. Invasion is the primary cause of therapeutic failure in the treatment of malignant gliomas. …

"In vivo angiogenesis data substantiate the in vitro data that TFPI-2 expression effectively inhibits new vessel formation," Dr. Yanamandra and colleagues note.

These data, they conclude, suggest that "targeting angiogenesis may have therapeutic value in the treatment of malignant gliomas."

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000